Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on , , and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at . We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
View source version on businesswire.com:
Investor:
Ian Estepan, 617-274-4052
[email protected]
Media:
Tracy Sorrentino, 617-301-8566
[email protected]
Source: Sarepta Therapeutics, Inc.